🧮 BCLI Net Income Breakdown
Understanding Net Income
Net income, also called the "bottom line" or net profit, is the money a company keeps after paying all expenses including cost of goods, operating costs, interest, and taxes. For BCLI, the trailing twelve month net income is $-10.5M.
Why Net Income Matters
Net income is the ultimate measure of accounting profitability. It determines earnings per share (EPS), affects stock valuations through the P/E ratio, and represents the theoretical amount available to shareholders. However, net income can be influenced by accounting choices, which is why value investors often look at cash flow metrics alongside it.
BCLI's net income growth rate of N/A (based on log-linear regression of 0 quarters) indicates relatively flat or slightly declining profitability.
Net Income vs Cash Flow Metrics
Free Cash Flow: $0 →
Actual cash generated after capital expenditures. FCF often differs from net income due to depreciation, working capital changes, and capex timing.
Owner Earnings: N/A →
Buffett's preferred metric that adds back depreciation but subtracts maintenance capex. Often considered more accurate than net income.
EPS (Diluted): $-0.86 →
Net income divided by diluted shares outstanding. The primary driver of the P/E ratio used in valuations.
Revenue: N/A →
The top line that net income is derived from. Net margin shows what percentage of revenue becomes profit.
P/E Ratio Analysis
BCLI's P/E ratio of N/A means investors pay $N/A for every $1 of annual earnings.
Net Margin: Profitability Efficiency
Net margin of N/A shows what percentage of BCLI's revenue converts to profit after all costs.
Summary: BCLI Net Income Trend
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) generated $-10.5M in trailing twelve-month net income, growing at N/A annually — a negative trend — revenue erosion that warrants monitoring. For complete financial analysis, view the full BCLI stock report on Zyberno.
Frequently Asked Questions
What is BCLI's current net income?
BRAINSTORM CELL THERAPEUTICS INC.'s TTM net income is $-10.5M, growing at N/A annually — a negative trend — revenue erosion that warrants monitoring.
Is BCLI's net income growing?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) generated $-10.5M in trailing twelve-month net income, growing at N/A annually — a negative trend — revenue erosion that warrants monitoring.
What is BCLI's net profit margin?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) generated $-10.5M in trailing twelve-month net income, growing at N/A annually — a negative trend — revenue erosion that warrants monitoring.
What is BCLI's P/E ratio?
BCLI's P/E ratio is N/A, meaning the market values the company at N/A times its annual earnings.
How does net income differ from free cash flow?
Net income is an accounting measure that includes non-cash items like depreciation, while free cash flow shows actual cash generated. BCLI's net income is $-10.5M versus free cash flow of $0. Large differences often indicate significant capital expenditures or working capital changes.
📊 Full BCLI Stock Report →
See BCLI's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.
💵 BCLI Free Cash Flow →
Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.
💰 BCLI Owner Earnings →
Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.
📈 BCLI Earnings Per Share →
Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.
🎯 BCLI Earnings Surprise (SUE) →
See whether BCLI is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.
📊 BCLI Revenue →
Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.
💰 BCLI Net Income →
Analyze the bottom-line profit, P/E ratio, and net profit margin trends.
🔶 BCLI Operating Income →
Analyze EBIT, operating margin, and core business profitability before interest and taxes.
💜 BCLI Gross Profit →
Analyze gross margin, pricing power, and profitability before operating expenses.